Accessibility Menu
SeaStar Medical logo

SeaStar Medical(NASDAQ) ICU

Current Price$3.75
Market Cap$14.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 YearN/A
1 Year-50%
1 Month+8%
SeaStar Medical last closing stock price
MetricPriceDate
Last closeUSD 3.742026-07-23
SeaStar Medical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-11.37%USD 4.222026-07-16
1 month+7.78%USD 3.472026-06-23
3 month-9.44%USD 4.132026-04-24
Year to date+55.83%USD 2.402025-12-31
1 year-49.53%USD 7.412025-07-23
3 year-97.07%USD 127.482023-07-24
Since inception-99.84%USD 2,450.002021-03-18

SeaStar Medical Financials at a Glance

Market Cap

$14.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.44M

Net Income (TTM)

-$11.90M

EPS (TTM)

-$4.78

P/E Ratio

-0.78

Dividend

$0.00

Beta (Volatility)

0.43 (Low)

Price

$3.75

Volume

20

Open

$3.75

Previous Close

$3.74

Daily Range

$3.75 - $3.75

52-Week Range

$2.07 - $12.50

Estimated Earnings Date

Aug 12, 2026

ICU News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About SeaStar Medical

SeaStar Medical helps hospitals treat severe inflammation in critically ill patients. Its main device supports children with kidney injury caused by infection. The company’s products aim to reduce harmful immune responses in hospital settings.

Products and Services

  • Selective Cytopheretic Device (SCD): Device that filters blood to calm overactive immune cells in patients with severe inflammation; primary source of revenue.
  • QUELIMMUNE: FDA-approved device for children with acute kidney injury from sepsis, used with continuous kidney support machines; primary source of revenue.
  • Pipeline Therapies: Devices in development for adults with kidney injury, heart and liver complications, and patients after heart surgery; no current revenue.
  • Contract Research: Research services for external partners studying SCD in heart failure; minor revenue contribution.

Growth and Expansion

  • Launched QUELIMMUNE for pediatric kidney injury in July 2024.
  • Ended exclusive distributor deal with Nuwellis in August 2024; shifted to direct sales model.
  • Signed supply agreement with Fresenius Medical Care North America for device components in 2024.
  • Started pivotal trial for adult kidney injury therapy in 2023.
  • Expanded FDA designations for new uses in heart, liver, and surgery patients between 2023 and 2025.

What Makes SeaStar Medical Stand Out

SeaStar Medical’s device works with existing hospital equipment, making adoption easier for intensive care units. Its technology targets harmful immune cells without weakening the whole immune system. The company holds exclusive patents and has FDA approval for a rare pediatric use.

Five Things You Need to Know

  • Revenue was $1.2 million in FY 2025, up 814% from FY 2024.
  • Gross margin reached 95.7% in FY 2025, reflecting high product value.
  • Net loss improved to $12.2 million in FY 2025, down 51% year-on-year.
  • Operating expenses fell 26% to $13.4 million in FY 2025.
  • Cash balance was $12.0 million at December 31, 2025, but not enough for 12 months’ operations.

Bottom Line

SeaStar Medical has shifted from research to commercial sales, focusing on rare pediatric kidney injury. The company faces funding and regulatory challenges as it seeks broader adoption.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

17

CEO

Eric Schlorff

Website

www.seastarmedical.com

Headquarters

Denver, CO 80216, US

ICU Financials

Key Financial Metrics (TTM)

Gross Margin

93.11%

Operating Margin

-832.45%

Net Income Margin

-828.62%

Return on Equity

-146.29%

Return on Capital

-111.28%

Return on Assets

-105.65%

Earnings Yield

-1.28%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$14.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

4.00M

Volume

20

Avg. Volume

92.17K

Financials (TTM)

Gross Profit

$1.34M

Operating Income

-$11.95M

EBITDA

-$11.95M

Operating Cash Flow

-$13.71M

Capital Expenditure

$0.00

Free Cash Flow

-$13.71M

Cash & ST Invst.

$9.35M

Total Debt

$331.00K

SeaStar Medical Performance Analysis

SeaStar Medical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 135,000N/A
20252025-12-31USD 1,234,000814.1%
SeaStar Medical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3015.4%
Q32025-09-30-45.9%
Q42025-12-31129.5%
Q12026-03-3117.9%
SeaStar Medical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -371.14321.2%
20232023-12-31USD -302.63-18.5%
20242024-12-31USD -66.33-78.1%
20252025-12-31USD -5.86-91.2%
SeaStar Medical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3075.0%
Q32025-09-30-18.2%
Q42025-12-3138.5%
Q12026-03-31-12.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$495.00K

+68.9%

Gross Profit

$449.00K

+53.2%

Gross Margin

90.71%

N/A

Market Cap

$14.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$879.34K

N/A

Employees

17

N/A

Net Income

-$3.52M

+6.7%

EBITDA

-$3.60M

+4.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$9.35M

+76.5%

Total Debt

$331.00K

-8.8%

Accounts Receivable

$179.00K

+62.7%

Inventory

$57.00K

+29.5%

Long Term Debt

$0.00

N/A

Short Term Debt

$331.00K

-8.8%

Return on Assets

-1.06%

N/A

Return on Invested Capital

-1.63%

N/A

Free Cash Flow

-$2.76M

-4.0%

Operating Cash Flow

-$2.76M

-4.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BLRXBioLineRx Ltd.
$2.93+2.27%
MBRXMoleculin Biotech, Inc.
$2.10+0.72%
LNAILunai Bioworks Inc.
$2.35+1.29%
APLMApollomics, Inc.
$18.90+0.21%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.54-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$64.95-0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$44.15+0.02%
CLFCleveland-Cliffs
$11.24+0.03%

Questions About ICU

What is the current price of SeaStar Medical?

SeaStar Medical is trading at $3.75 per share.

What is the 52-week range for SeaStar Medical?

Over the past 52 weeks, SeaStar Medical has traded between $2.07 and $12.50.

How much debt does SeaStar Medical have?

As of the most recent reporting period, SeaStar Medical reported total debt of $331.00K.

How much cash does SeaStar Medical have on hand?

SeaStar Medical reported $9.35M in cash and cash equivalents in its most recent financial results.

What is SeaStar Medical’s dividend yield?

SeaStar Medical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services